Arcus Biosciences, Inc. (RCUS)
30.12
+0.27
(+0.90%)
USD |
NYSE |
Sep 03, 16:00
30.12
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Research and Development Expense (TTM) : 497.00M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 497.00M |
| March 31, 2026 | 523.00M |
| December 31, 2025 | 523.00M |
| September 30, 2025 | 503.00M |
| June 30, 2025 | 485.00M |
| March 31, 2025 | 461.00M |
| December 31, 2024 | 448.00M |
| September 30, 2024 | 440.00M |
| June 30, 2024 | 399.00M |
| March 31, 2024 | 368.00M |
| December 31, 2023 | 340.00M |
| September 30, 2023 | 327.20M |
| June 30, 2023 | 321.88M |
| March 31, 2023 | 307.79M |
| December 31, 2022 | 288.00M |
| September 30, 2022 | 257.74M |
| June 30, 2022 | 252.31M |
| Date | Value |
|---|---|
| March 31, 2022 | 251.17M |
| December 31, 2021 | 256.35M |
| September 30, 2021 | 255.12M |
| June 30, 2021 | 235.67M |
| March 31, 2021 | 202.59M |
| December 31, 2020 | 159.35M |
| September 30, 2020 | 131.32M |
| June 30, 2020 | 96.76M |
| March 31, 2020 | 86.07M |
| December 31, 2019 | 78.48M |
| September 30, 2019 | 69.23M |
| June 30, 2019 | 64.85M |
| March 31, 2019 | 53.55M |
| December 31, 2018 | 49.65M |
| September 30, 2018 | 50.36M |
| June 30, 2018 | 58.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Halozyme Therapeutics, Inc. | 102.37M |
| AVITA Medical, Inc. | 20.15M |
| Iovance Biotherapeutics, Inc. | 267.71M |
| Editas Medicine, Inc. | 82.53M |
| Recursion Pharmaceuticals, Inc. | 344.11M |